Thyroid medication recall upgraded to FDA's highest risk level
Published September 24, 2026 2:52 PM CDT article Vitruvias Therapeutics, Inc., issued a recall on a single lot of its Thyroid Tablets.
Published September 24, 2026 2:52 PM CDT article Vitruvias Therapeutics, Inc., issued a recall on a single lot of its Thyroid Tablets. (FDA) A thyroid medication recall announced last month has been upgraded to the highest risk level allotted by federal regulators, according to the Food and Drug Administration.
Vitruvias Therapeutics Inc. voluntarily recalled one lot of its Thyroid Tablets, USP 30 mg, in late August because "testing confirmed the potential for the product to be superpotent." On Tuesday, the recall was upgraded to Class I, "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death." Thyroid medication recalled By the numbers: The lot number for the recalled thyroid tablets is 504950.
First reported by Fox 7 Austin.
More in Health & Nutrition
- Long-term opioid use fails to alleviate chronic back pain, Northwestern University study suggests
Researchers identified distinct brain activity patterns and molecular markers that may guide future treatments for pain management and opioid tapering.
- Human tau seeds trigger disease-specific shapes in mouse brains, new study finds
Study in Nature shows that injectable human tau aggregates from Alzheimer’s and corticobasal degeneration template their 3D folds onto mouse tau, supporting the prion-like seeding model.
- Menopause Largely Missing from Electronic Health Records Despite Its Health Impact
study of nearly 240,000 women finds only 12% of electronic records include menopause status, even though over half reported being in transition.